Eliquis

German Panel Saw Little to No Added Benefit for Pfizer’s Eliquis
German Panel Saw Little to No Added Benefit for Pfizer’s Eliquis
Bloomberg
Pfizer
Germany
Eliquis
Bristol-Myers Squibb
Flag link:
FDA Delays Eliquis Verdict
FDA Delays Eliquis Verdict
Yahoo/Zacks
Eliquis
Bristol-Myers Squibb
Pfizer
anti-clotting
Flag link:
Pfizer and Bristol-Myers’ Blood Thinner Delayed by FDA
Pfizer and Bristol-Myers’ Blood Thinner Delayed by FDA
Bloomberg
Pfizer
bloodthinners
FDA
Eliquis
Bristol-Myers Squibb
Flag link:
Will FDA Delay Approving The Eliquis Bloodthinner?
Will FDA Delay Approving The Eliquis Bloodthinner?
Pharmalot
FDA
bloodthinners
Eliquis
Flag link:
Replacing Coumadin: A $10 Billion Opportunity
Replacing Coumadin: A $10 Billion Opportunity
Seeking Alpha
Coumadin
Eliquis
Pfizer
Apixaban
Bristol-Myers Squibb
Xarelto
Bayer
JNJ
Pradaxa
Boehringer Ingelheim
Flag link:
22 Hot Drugs Facing FDA Approval in 2012
22 Hot Drugs Facing FDA Approval in 2012
TheStreet.com
Amarin
AMR101
Ironwood
linaclotide
Merck
Ariad
ridaforolimus
Vivus
Qnexa
Avanafil
Amgen
Xgeva
Cell Therapeutics
pixantrone
Kalydeco
Vertex
ONYX Pharmaceuticals
Carfilzomib
Pfizer
Bristol-Myers Squibb
Eliquis
Chelsea Therapeutics
Northera
Levadex
MAP Pharmaceuticals
Roche
Curis
vismodegib
Biogen Idec
Elan
Tysabri
Amylin
Bydureon
Dapagliflozin
Uplypso
Protalix BioTherapeutics
Teva Pharmaceuticals
BioSante
Bio-T-Gel
Corlux
Corcept Therapeutics
Discovery Labs
Surfaxin
Flag link:
Bristol-Pfizer drug gets FDA priority review
Bristol-Pfizer drug gets FDA priority review
Reuters
Pfizer
FDA
Bristol-Myers Squibb
anticlotting
Eliquis
Flag link:
Pfizer, Bristol-Myers’ Eliquis Recommended by U.K. Cost Agency
Pfizer, Bristol-Myers’ Eliquis Recommended by U.K. Cost Agency
Bloomberg
Pfizer
Bristol-Myers Squibb
Eliquis
anti-clotting
Flag link:
Quick review of Eliquis could lift Bristol, Pfizer
Quick review of Eliquis could lift Bristol, Pfizer
Reuters
Pfizer
Eliquis
Bristol-Myers Squibb
bloodthinner
Flag link:
Bristol, Pfizer clot drug fails to help ill patients
Bristol, Pfizer clot drug fails to help ill patients
Reuters
Bristol-Myers Squibb
Pfizer
Eliquis
Apixaban
anticoagulants
Flag link:
Analyst Says Xarelto Niche "Still Secure"
Analyst Says Xarelto Niche "Still Secure"
Forbes
Xarelto
bloodthinners
Bayer
JNJ
Pfizer
Bristol-Myers Squibb
Eliquis
Flag link:
Pfizer, Bristol-Myers May Lead $9B Stroke Market
Pfizer, Bristol-Myers May Lead $9B Stroke Market
Bloomberg
stroke
bloodthinners
Pfizer
Eliquis
Bristol-Myers Squibb
Flag link:
ELIQUIS® (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly Less Major Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE Trial
ELIQUIS® (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly Less Major Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE Trial
Yahoo/BusinessWire
Eliquis
Apixaban
Warfarin
atrial fibrillation
stroke
Bristol-Myers Squibb
Pfizer
ARISTOTLE trial
Flag link:
Pfizer & Bristol-Myers to Release Highly Anticipated Data on Bloodthinner Hopeful
Pfizer & Bristol-Myers to Release Highly Anticipated Data on Bloodthinner Hopeful
Motley Fool
Pfizer
Bristol-Myers Squibb
Eliquis
bloodthinners
Apixaban
Flag link:
Data may prove Bristol, Pfizer drug a winner
Data may prove Bristol, Pfizer drug a winner
Yahoo/Reuters
Pfizer
stroke
Bristol-Myers Squibb
bloodthinners
Eliquis
Apixaban
Flag link:
Anti-Coagulant Blockbuster Drugs Are Here
Anti-Coagulant Blockbuster Drugs Are Here
Seeking Alpha
anticlotting
blood thinners
JNJ
Pfizer
AstraZeneca
Bristol-Myers Squibb
Bayer
Xarelto
Pradaxa
Boehringer Ingelheim
Eliquis
Flag link:
Biotech Clinical Trials Update for 3 Drug Manufacturers
Biotech Clinical Trials Update for 3 Drug Manufacturers
Seeking Alpha
Pfizer
Cel-Sci
Bristol-Myers Squibb
Eliquis
Multikine
Flag link:
EMA Recommends Approval for Pfizer, Bristol-Myers’ Eliquis
EMA Recommends Approval for Pfizer, Bristol-Myers’ Eliquis
Bloomberg
EMA
Europe
Eliquis
Pfizer
blood thinners
Apixaban
Flag link:

Pages